Fig. 4.1 Boundaries of template RPLND according to schools. (a) Original full bilateral RPLND. (b) Modified template dissections (right and left) as proposed at Indiana University. (c) Reduced modified template…
Fig. 11.1 Cold-induced Raynaud phenomenon of the fingers in a cisplatin-treated TCSs 11.6 Neurotoxicity Determination of neurotoxicity is a complex task and most precisely performed by neurophysiologic examinations, which are…
Histology Initial stage Therapy Relapse rate (%) Relapse rate >2 years Main area of relapse Reference Seminoma I Surveillance 12–31 3–5 % Abdomen [16–18] 1 % >3 years Seminoma I…
Conventional–dose chemotherapy (CDCT) VIP Cisplatin 20 mg/m2 Days 1–5 4 cycles Ifosfamide 1.2 g/m2 Days 1–5 Etoposide 75 mg/m2 Days 1–5 TIP Cisplatin 20 mg/m2 Days 1–5 4 cycles Ifosfamide…
Treatment Alla LVI + LVI − Surveillanceb BEP × 1c Surveillanceb BEP × 1c Surveillanceb BEP × 1c Number of patients 1,000 1,000 1,000 1,000 1,000 1,000 Relapses 250 21 500 32 150 16 Total number…
Criteria for intermediate-risk patients by IGCCCG criteria Status Seminoma Nonseminoma Intermediate risk Nonpulmonary visceral metastases present AFP 1,000–10,000 ng/mL Any hCG hCG 5,000–50,000 mU/mL Any LDH LDH 3–10.0 upper limit…
Localization of the tumour Size Multiplicity Extension of the tumour (pT category according to UICC) Histopathological type (WHO) In seminoma: presence of syncytiotrophoblasts In spermatocytic seminoma: any sarcomatous elements In…
Treatment option USA (N:261)a (%) Europe (N:969) (%) RAD Chemotherapy Surveillance Several options 62b 3b 21b 19 21 18 42 Vossen et al. [32] Arvold et al. [31] aCompliance rate,…
Chemotherapy Classification system Number of patients Favourable response rates (%) Progression-free survival (%) Conclusion First author BEP × 4 Indiana University 159 73 61 Double-dose cisplatin not superior and more toxic Nichols…
Rectum Sigmoid and left colon Transverse colon Right colon Ileum Deep ulceration (12 if present, 0 if absent) 0+ 0+ 12+ 12+ / Superficial ulceration (6 if present, 0…
